Page 83 - 《中国药房》2023年12期

·药物与临床·

利拉鲁肽致胰腺炎的文献病例分析
Δ

1 #
1
1
1＊
卢翠翠 ，弭 玮 ，李 霞 ，张旭升 ，沈承武 （1.山东第一医科大学附属省立医院药学部，济南 250021；2.山
2
东省药品不良反应监测中心，济南 250014）
中图分类号 R969.3 文献标志码 A 文章编号 1001-0408（2023）12-1483-05
DOI 10.6039/j.issn.1001-0408.2023.12.14

摘 要 目的 分析利拉鲁肽致胰腺炎的临床特点，为临床合理用药提供参考。方法 计算机检索中国知网、维普网、万方数据、
PubMed、Web of Science和Medline数据库，收集利拉鲁肽致胰腺炎的个案报道，检索时限为从建库起至2022年12月31日，描述性
分析患者人口学特征、用药情况、临床表现、干预与转归等。结果 共纳入文献17篇，涉及17例患者，其中男性7例、女性10例，年
龄为25～75岁；均有用药指征，包括2型糖尿病14例，肥胖或超重3例；其中单一用药5例，合并用药12例。17例患者胰腺炎的发
生时间均为利拉鲁肽用药后1 d～11个月，大多出现在6个月以内（14例）；主要临床表现包括腹痛、恶心和呕吐等。诊断为胰腺炎
后，16例停用利拉鲁肽，其中1例未予其他干预，15例予以对症治疗，16例患者症状均缓解，但2例在利拉鲁肽停用数周后再次发
生胰腺炎，且均为重度胰腺炎，1 例患者再次应用利拉鲁肽后胰腺炎再次发生。关联性评价结果显示，1 例为“肯定”，4 例为“可
能”，其余患者为“很可能”。结论 利拉鲁肽致胰腺炎多发生在用药6个月内，多为轻度、中重度，但也可能出现严重甚至致命的病
例。临床在应用利拉鲁肽时，应定期监测患者胰酶水平并密切观察其临床表现，若出现疑似利拉鲁肽诱发的胰腺炎，应尽早停药
并给予对症治疗。
关键词 利拉鲁肽；胰腺炎；2型糖尿病；胰高血糖素样肽-1受体激动剂；文献病例分析

Literature case analysis of liraglutide-induced pancreatitis
1
1
2
1
LU Cuicui ，MI Wei ，LI Xia ，ZHANG Xusheng ，SHEN Chengwu（1. Dept. of Pharmacy， Shandong Provincial
1
Hospital Affiliated to Shandong First Medical University， Jinan 250021， China；2. Shandong Provincial Center
for Adverse Drug Reaction Monitoring， Jinan 250014， China）
ABSTRACT OBJECTIVE To analyze the clinical characteristics of liraglutide-induced pancreatitis， and to provide reference for
clinical rational drug use. METHODS Retrieved from CNKI， VIP， Wanfang database， PubMed， Web of Science and Medline，
case reports about liraglutide-induced pancreatitis were collected from the inception to December 31st， 2022. Demographic
characteristics， drug use， clinical manifestations， intervention and outcome were analyzed using descriptive statistical method.
RESULTS A total of 17 pieces of literature were collected and 17 patients were involved， including 7 males and 10 females. The
patients aged from 25 to 75 years. All 17 patients had drug indications， including 14 cases of type 2 diabetes mellitus， 3 cases of
obesity or overweight. Among 17 patients， liraglutide was used alone in 5 cases， and combined with other drugs in 12 cases. Time
from liraglutide administration to pancreatitis occurrence ranged from 1 day to 11 months after medication in 17 patients， with 14
cases less than 6 months. The clinical manifestations mainly included abdominal pain， nausea and vomiting， etc. After the diagnosis
of pancreatitis， liraglutide discontinuation occurred in 16 patients； 1 case did not receive any other interventions and the other 15
cases were managed with symptomatic supportive treatment； the symptoms of all 16 patients resolved； however， 2 patients suffered
from second episode of severe pancreatitis several weeks after liraglutide discontinuation， pancreatitis recurred after liraglutide
rechallenge in 1 case. The results of correlation evaluation showed that 1 case was “positive”， 4 cases were “possible”， and the
remaining patients were “very likely”. CONCLUSIONS Liraglutide-induced pancreatitis mainly occurred within 6 months after
drug administration. The majority of liraglutide-induced pancreatitis cases are mild to moderate， but there are also severe and even
fatal cases. It is advisable to periodically monitor the level of
Δ 基金项目 山东省药品化妆品不良反应监测哨点课题（No.
pancreatic enzymes and closely observe patients’ clinical mani-
2022SDADRKY01）；山东省医学会临床药学科研专项资金项目（No.
festations. In case of suspected liraglutide-induced pancreatitis，
YXH2022ZX001）；医院药物警戒研究协作组医院药学科研专项课题
drug withdrawal and symptomatic treatment should be taken
（No.DRM2022018）
immediately.
＊第一作者 副主任药师，博士。研究方向：临床药学。电话：
0531-68776449。E-mail：cece2021@163.com KEYWORDS liraglutide； pancreatitis； type 2 diabetes
# 通信作者 主任药师，硕士。研究方向：医院药学。电话：0531- mellitus； glucagon-like peptide-1 receptor agonist； literature
68776461。E-mail：scw_810@163.com case analysis

中国药房 2023年第34卷第12期 China Pharmacy 2023 Vol. 34 No. 12 · 1483 ·